These findings implicate CCL5, CCR3/CCR5, and ERK1/2 survival signaling pathways as potential therapeutic targets for clearing persistent ZIKV infections and preventing ZIKV spread and neurovirulence. The gene discussed is MAPK3; the disease is Zika virus infectious disease.